guest ::
| Home > Publications Database > Systemic administration of epothilone D improves functional recovery of walking after rat spinal cord contusion injury. > print |
| Home > Publications Database > Systemic administration of epothilone D improves functional recovery of walking after rat spinal cord contusion injury. > print |
| 001 | 140031 | ||
| 005 | 20240321220730.0 | ||
| 024 | 7 | _ | |a 10.1016/j.expneurol.2017.12.001 |2 doi |
| 024 | 7 | _ | |a pmid:29223322 |2 pmid |
| 024 | 7 | _ | |a 0014-4886 |2 ISSN |
| 024 | 7 | _ | |a 1090-2430 |2 ISSN |
| 024 | 7 | _ | |a altmetric:30282663 |2 altmetric |
| 037 | _ | _ | |a DZNE-2020-06353 |
| 041 | _ | _ | |a English |
| 082 | _ | _ | |a 610 |
| 100 | 1 | _ | |a Ruschel, Jörg |0 P:(DE-2719)2810285 |b 0 |e First author |u dzne |
| 245 | _ | _ | |a Systemic administration of epothilone D improves functional recovery of walking after rat spinal cord contusion injury. |
| 260 | _ | _ | |a Orlando, Fla. |c 2018 |b Academic Press |
| 264 | _ | 1 | |3 print |2 Crossref |b Elsevier BV |c 2018-08-01 |
| 336 | 7 | _ | |a article |2 DRIVER |
| 336 | 7 | _ | |a Output Types/Journal article |2 DataCite |
| 336 | 7 | _ | |a Journal Article |b journal |m journal |0 PUB:(DE-HGF)16 |s 1685109835_10313 |2 PUB:(DE-HGF) |
| 336 | 7 | _ | |a ARTICLE |2 BibTeX |
| 336 | 7 | _ | |a JOURNAL_ARTICLE |2 ORCID |
| 336 | 7 | _ | |a Journal Article |0 0 |2 EndNote |
| 520 | _ | _ | |a Central nervous system (CNS) injuries cause permanent impairments of sensorimotor functions as mature neurons fail to regenerate their severed axons. The poor intrinsic growth capacity of adult CNS neurons and the formation of an inhibitory lesion scar are key impediments to axon regeneration. Systemic administration of the microtubule stabilizing agent epothilone B promotes axon regeneration and recovery of motor function by activating the intrinsic axonal growth machinery and by reducing the inhibitory fibrotic lesion scar. Thus, epothilones hold clinical promise as potential therapeutics for spinal cord injury. Here we tested the efficacy of epothilone D, an epothilone B analog with a superior safety profile. By using liquid chromatography and mass spectrometry (LC/MS), we found adequate CNS penetration and distribution of epothilone D after systemic administration, confirming the suitability of the drug for non-invasive CNS treatment. Systemic administration of epothilone D reduced inhibitory fibrotic scarring, promoted regrowth of injured raphespinal fibers and improved walking function after mid-thoracic spinal cord contusion injury in adult rats. These results confirm that systemic administration of epothilones is a valuable therapeutic strategy for CNS regeneration and repair after injury and provides a further advance for potential clinical translation. |
| 536 | _ | _ | |a 341 - Molecular Signaling (POF3-341) |0 G:(DE-HGF)POF3-341 |c POF3-341 |f POF III |x 0 |
| 542 | _ | _ | |i 2018-08-01 |2 Crossref |u https://www.elsevier.com/tdm/userlicense/1.0/ |
| 588 | _ | _ | |a Dataset connected to CrossRef, PubMed, |
| 700 | 1 | _ | |a Bradke, Frank |0 P:(DE-2719)2810270 |b 1 |u dzne |
| 773 | 1 | 8 | |a 10.1016/j.expneurol.2017.12.001 |b : Elsevier BV, 2018-08-01 |p 243-249 |3 journal-article |2 Crossref |t Experimental Neurology |v 306 |y 2018 |x 0014-4886 |
| 773 | _ | _ | |a 10.1016/j.expneurol.2017.12.001 |g Vol. 306, p. 243 - 249 |0 PERI:(DE-600)1466932-8 |q 306<243 - 249 |p 243-249 |t Experimental neurology |v 306 |y 2018 |x 0014-4886 |
| 856 | 4 | _ | |u https://www.sciencedirect.com/science/article/abs/pii/S0014488617303308?via%3Dihub |
| 909 | C | O | |p VDB |o oai:pub.dzne.de:140031 |
| 910 | 1 | _ | |a Deutsches Zentrum für Neurodegenerative Erkrankungen |0 I:(DE-588)1065079516 |k DZNE |b 0 |6 P:(DE-2719)2810285 |
| 910 | 1 | _ | |a Deutsches Zentrum für Neurodegenerative Erkrankungen |0 I:(DE-588)1065079516 |k DZNE |b 1 |6 P:(DE-2719)2810270 |
| 913 | 1 | _ | |a DE-HGF |b Gesundheit |l Erkrankungen des Nervensystems |1 G:(DE-HGF)POF3-340 |0 G:(DE-HGF)POF3-341 |3 G:(DE-HGF)POF3 |2 G:(DE-HGF)POF3-300 |4 G:(DE-HGF)POF |v Molecular Signaling |x 0 |
| 914 | 1 | _ | |y 2018 |
| 915 | _ | _ | |a Nationallizenz |0 StatID:(DE-HGF)0420 |2 StatID |d 2022-11-10 |w ger |
| 915 | _ | _ | |a JCR |0 StatID:(DE-HGF)0100 |2 StatID |b EXP NEUROL : 2021 |d 2022-11-10 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0200 |2 StatID |b SCOPUS |d 2022-11-10 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0300 |2 StatID |b Medline |d 2022-11-10 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0600 |2 StatID |b Ebsco Academic Search |d 2022-11-10 |
| 915 | _ | _ | |a Peer Review |0 StatID:(DE-HGF)0030 |2 StatID |b ASC |d 2022-11-10 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0199 |2 StatID |b Clarivate Analytics Master Journal List |d 2022-11-10 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0150 |2 StatID |b Web of Science Core Collection |d 2022-11-10 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)1050 |2 StatID |b BIOSIS Previews |d 2022-11-10 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)1030 |2 StatID |b Current Contents - Life Sciences |d 2022-11-10 |
| 915 | _ | _ | |a IF >= 5 |0 StatID:(DE-HGF)9905 |2 StatID |b EXP NEUROL : 2021 |d 2022-11-10 |
| 920 | 1 | _ | |0 I:(DE-2719)1013002 |k AG Bradke |l Axon Growth and Regeneration |x 0 |
| 980 | _ | _ | |a journal |
| 980 | _ | _ | |a VDB |
| 980 | _ | _ | |a I:(DE-2719)1013002 |
| 980 | _ | _ | |a UNRESTRICTED |
| Library | Collection | CLSMajor | CLSMinor | Language | Author |
|---|